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Mesenchymal stromal cells (MSCs) orchestrate tissue repair by releasing cell-derived 
microvesicles (MVs), which, presumably by small RNA species, modulate global gene 
expression. The knowledge of miRNA/mRNA signatures linked to a reparative status 
may elucidate some of the molecular events associated with MSC protection. Here, 
we used a model of cisplatin-induced kidney injury (acute kidney injury) to assess how 
MSCs or MVs could restore tissue function. MSCs and MVs presented similar protective 
effects, which were evidenced in  vivo and in  vitro by modulating apoptosis, inflam-
mation, oxidative stress, and a set of prosurvival molecules. In addition, we observed 
that  miRNAs (i.e., miR-880, miR-141, miR-377, and miR-21) were modulated, thereby 
showing active participation on regenerative process. Subsequently, we identified that 
MSC regulates a particular miRNA subset which mRNA targets are associated with Wnt/
TGF-β, fibrosis, and epithelial–mesenchymal transition signaling pathways. Our results 
suggest that MSCs release MVs that transcriptionally reprogram injured cells, thereby 
modulating a specific miRNA–mRNA network.
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highlighTs
•	 Mesenchymal	stromal	cells	promote	tissue	cytoprotection.
•	 Microvesicles	secreted	by	MSCs	reprogram	tubular	cells.
•	 MSCs	modulate	 an	 internal	 regulatory	miRNA–mRNA	net-
work	that	is	associated	with	tissue	repair.
inTrODUcTiOn
Mesenchymal	 stromal	 cells	 (MSCs)	 have	 a	 secretory	 potential	
that	has	been	therapeutically	explored	in	regenerative	medicine	
using	experimental	models	or	pivotal	clinical	studies	(1).	In	this	
context,	it	is	known	that	MSCs	can	modulate	gene	expression	by	
releasing	extracellular	microvesicles	(MVs)	to	orchestrate	tissue	
repair	 (2).	 Functionally,	 MSC-derived	MVs	 (MSC-MVs)	 have	
the	potential	to	transfer	many	sources	of	molecular	information,	
including	non-coding	small	regulatory	RNAs,	which	can	induce	
a	pleiotropic	 effect	on	 target	 cells	 (3,	4).	Although	not	 entirely	
elucidated,	 the	 mechanism	 of	 transcriptional	 reprograming	 of	
recipient	 cells	 seems	 to	be	achieved	via	 the	horizontal	 transfer	
of	specific	RNA	species	(microRNAs)	that	are	enriched	inside	of	
MVs	(5).	Moreover,	the	MSC-MVs	also	contain	ribonucleopro-
teins	related	to	intracellular	traffic	and	compartmentalization	of	
RNAs	(i.e.,	TIA,	HuR,	Ago2,	and	Stau-1	and	-2),	 thereby	high-
lighting	the	presence	of	an	organized	paracrine	process	that	may	
redirect	 cell	 fate	via	 cell-to-cell	 communication	 (6).	 In	 light	of	
these	properties,	some	evidences	have	suggested	that	the	transfer	
of	molecular	 information	mediated	by	MVs	plays	a	key	role	 in	
embryonic	development,	tissue	regeneration,	pathophysiological	
disorders,	and	homeostasis	dynamics	(7,	8).
To	date,	some	studies	have	exploited	the	therapeutic	potential	
of	 MSC-MVs.	 In	 a	 model	 of	 acute	 kidney	 injury	 (AKI),	 the	
infusion	of	MSC-MVs	promoted	the	activation	of	a	prosurvival	
program	 in	 injured	 tubular	 epithelial	 cells	 with	 reduction	 of	
apoptosis	 and	 improvement	 of	 cell	 proliferation	 rates	 via	 a	
horizontal	 transfer	of	RNAs	 (9,	10).	MSC-MVs	have	also	been	
tested	 in	 myocardial	 infarction	 models,	 where	 they	 reduced	
the	 necrotic	 area	 and	 enhanced	 blood	 flow	 recovery	 (11,	 12).	
Furthermore,	in	acute	lung	injury	models,	MSC-MV	treatment	
reduced	 pulmonary	 edema,	 hypertension,	 and	 lung	 protein	
permeability	and	suppressed	the	 innate	 inflammatory	response	
(13,	14).	Complementarily,	Zhang	 et  al.	 demonstrated	 that	 the	
graphical absTracT | de almeida et al. found that mesenchymal stromal cells via cell-derived microvesicles modulate a mirna/mrna network 
that is linked with Wnt/TgF-β, fibrosis, and epithelial–mesenchymal transition signaling pathways. The authors detected that mirnas mir-880, 
mir-141, mir-377, and mir-21 are modulated, and they can be associated to internal reprograming of tubular epithelial cells promoting tissue 
repair.
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injection	of	MSC-MVs	can	decrease	allograft	skin	rejection	via	a	
mechanism	that	is	dependent	on	Tregs	polarization	(15).	Other	
studies	 also	 identified	 that	MSC-MVs	 inoculation	 induced	 an	
efficient	 regeneration	 of	 sciatic	 nerve	 with	 the	 promotion	 of	
neurovascular	 remodeling	 and	 functional	 recovery	 after	 stroke	
(16,	17).	Although	these	results	have	demonstrated	the	potential	
efficacy	of	MSC-MVs	for	tissue	repair	in	distinct	conditions,	little	
yet	is	known	about	the	precise	molecular	mechanisms	involved	in	
this	regenerative	process.
To	address	 this	 issue	and	clarify	some	of	 the	aspects	related	
to	 cell-based	 therapies	 for	 kidney	 diseases,	 we	 tested	 here	 the	
hypothesis	 that	 MSC-MVs	 could	 promote	 tissue	 recovery	 by	
modulating	a	specific	miRNA–mRNA	regulatory	network,	which	
is	able	to	control	injury	responses	and	chronic	damage.	More	spe-
cifically,	we	used	a	classical	toxic	model	of	cisplatin-induced	AKI	
and	assessed	how	MSCs	or	their	secreted	MVs	could	restore	renal	
tissue	function	by	modulating	the	miRNA	expression	profile	and	
a	specific	miRNA–mRNA	network.
MaTerials anD MeThODs
isolation, characterization, and culture of 
Mscs and MVs
The	MSCs	were	isolated	from	adult	male	mice	inguinal	adipose	
tissue,	washed	 in	sterile	PBS	(2×),	minced	 in	small	pieces,	and	
submitted	 to	 enzymatic	 digestion	by	 37°C	with	 collagenase	 IA	
0.1%	(Sigma,	USA).	In	sequence,	these	cells	were	filtered	in	cell	
strainer	 (100 µm,	BD,	Beckton	Dickson,	USA),	 rewashed	 (2×)	
using	complete	medium,	and	cultivated	at	37°C	in	a	humidified	
atmosphere	with	5%	CO2	in	D-MEM	low	glucose	culture	medium	
(45 mM	NaHCO3,	10%	FBS,	100 U/ml	penicillin,	100 U/ml	strep-
tomycin)	(n = 5).	The	differentiation	into	mesenchymal	lineages	
in vitro	(i.e.,	adipocytes,	osteoblasts,	and	chondrocytes)	was	per-
formed	using	six-well	plates	(TPP,	USA)	during	15–20 days	with	
adipogenesis,	 chondrogenesis,	 and	 osteogenesis	 Mesenchymal	
Stem	Cell	Kit	(Millipore,	USA),	according	to	the	manufacturer’s	
specifications	(n = 5).	For	MV	isolation,	the	24h	MSC	serum-free	
supernatant	was	 submitted	 to	pre-centrifugation	 at	 2,000  g	 for	
5 min	and	after	to	ultracentrifugation	at	100,000 g	for	2 h.	Then,	
the	pellet	was	suspended	in	sterile	PBS	with	0.1%	of	BSA	and	kept	
at	−80°C.	Furthermore,	MVs	were	evaluated	according	to	their	
size	properties	using	a	NanoSight	instrument	(Malvern,	UK).	The	
content	of	small	RNAs	or	miRNAs	inside	of	MVs	was	verified	with	
a	capillary	electrophoresis	method	using	the	Agilent	small	RNA	
kit,	 strictly	 following	 the	 manufacturer’s	 instructions	 (Agilent	
Technologies,	 Santa	Clara,	 CA,	USA)	 (n =  5).	 Two	 additional	
groups	 consisting	 of	MVs	 treated	with	 RNAse	A	 (100  µg/mL,	
Thermo	Scientific,	USA)	and	ultracentrifuged	medium	without	
cells	were	carried	out	concomitantly,	and	all	samples	were	read	
with	 an	Agilent	2100	Bioanalyzer	 (Agilent	Technologies,	 Santa	
Clara,	CA,	USA)	(n = 5).	The	immunophenotyping	of	MSCs	and	
MVs	was	performed	using	specific	sets	of	antibodies	(i.e.,	CD44,	
CD90,	CD105,	CD73,	CD45,	CD34,	CD11c,	CD106,	CD31,	CD9,	
and	CD69,	BD	Bioscience,	USA),	according	to	the	manufacturer’s	
recommendations	 (n  =  5).	 Briefly,	 cells	 were	 washed	 (PBS),	
centrifugated	(2,000 g	at	5 min),	and	incubated	(45 min	in	dark	
room)	 with	 specific	 antibody	 at	 1:100	 dilution	 and	 rewashed	
afterward	 in	FACs	buffer	 (PBS	2%	FBS).	A	FACSCanto	 II	flow	
cytometer	(BD,	Beckton	Dickson)	was	used	for	cell	acquisition,	
and	the	FlowJo	software	was	used	for	data	analysis.
coculture of Mscs or MVs with renal 
Tubular cells
For	 in  vitro	 assays,	 approximately	 2  ×  105	 of	 renal	 epithelial	
tubular	 cells	 (MM55.K,	ATCC®	CRL-6436TM)	were	 seeded	 in	
six-well	 plates	 (TPP,	 USA)	 and	 treated	 with	 nephrotoxic	 drug	
cisplatin	(8 µg/mL)	for	48 h,	and	two	additional	treated	groups	
with	cisplatin	were	co-cultured	 in	contact	with	MSCs	 (v/v	1:1,	
1 × 105)	or	MVs	(50 µg/ml,	sequentially	each	6 h)	for	48 h	(Figure	
S4C	in	Supplementary	Material).	Subsequently,	cells	were	trypsi-
nized	and	subjected	to	analysis	for	apoptosis,	cell	proliferation,	
and	 oxidative	 stress	 analysis	 using	 the	 respective	 kits:	 Alexa	
Fluor®	 488	 annexin	 V/Dead	 Cell	 Apoptosis	 kit,	 CellTrace™	
Violet	Cell	Proliferation	kit,	and	MitoSOX™	Red	Mitochondrial	
Superoxide	Indicator	kit	(Life	Technologies,	USA),	following	the	
manufacturer’s	recommendations	(n = 6).	For	apoptosis	analysis,	
a	range	of	cisplatin	was	utilized	as	death	curve	(1–10 µg/mL)	and	
newly	 a	 dose	 of	 8  µg/mL	was	 established	 for	 additional	 assays	
(Figure	S4D	in	Supplementary	Material).	Two	additional	groups	
without	co-culture	were	processed	with	tubular	cells	treated	and	
untreated	with	cisplatin.	During	the	flow	cytometry	analysis	to	
distinguish	 the	 tubular	 cells	 population	 (MM55.K	 cells)	 from	
MSCs,	 the	MSCs	 population	 were	 previously	 labeled	 with	 the	
fluorescent	dye	CellTrace™		Violet	(Cell	Trace	Violet	Proliferation	
Kit,	Life	Technologies,	USA)	and	excluded	 from	analysis	using	
negative	gate	strategy	in	flow	cytometry	workflow	(Figure	S4E	in	
Supplementary	Material).	For	visualizing	the	MVs	incorporation	
process,	 the	MVs	were	prelabeled	with	PKH26	 red-fluorescent	
dye	(Sigma,	USA)	and	co-cultured	in	chamber	slide	system	with	
tubular	cells	(1 × 104/well)	treated	with	cisplatin	(8 µg/mL)	in	a	
time-course	assay	per	24 h.	Images	were	recorded	at	each	time	
point	to	observe	MVs	incorporation	into	tubular	cells	(NIS	ele-
ments	microscope	Nikon).
animal experiments and study groups
For	all	animal	experiments,	we	used	adult	C57BL/6	mice,	aged	
8–12 weeks	with	20–30 g	weight	(n = 8	per	group).	The	animals	
were	 housed	 in	 polypropylene	 boxes	 at	 controlled	 room	 tem-
perature	and	 light	conditions	 (22°C	and	12-h	 light/12-h	dark).	
They	received	a	solid	diet	and	filtered	water	ad libitum.	All	animal	
handling	protocols	were	approved	by	the	local	Animal	Care	com-
mittee	CEP/UNIFESP	No.	1058/10.	Animals	were	separated	into	
three	 study	 groups	 according	 to	 the	 experimental	 procedures:	
mice	 treated	 with	 saline	 solution,	 mice	 treated	 with	 cisplatin,	
and	mice	treated	with	cisplatin	but	also	transplanted	with	MSCs	
or	MVs.
In Vivo Model of aKi and infusion of Mscs 
or MVs
To	develop	the	in vivo	experimental	model	of	toxic	AKI,	an	intra-
peritoneal	infusion	with	15 mg/kg	of	cisplatin	(Pfizer,	USA)	was	
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performed	(n = 8	per	group).	The	control	group	was	administered	
with	300 µL	phosphate	buffer	(PBS).	After	24 h	of	cisplatin	treat-
ment	 (day +  1),	 1 ×  106	 of	MSCs	or	300 µL	of	 saline	 solution	
(Sham	 group)	 were	 infused	 intraperitoneally	 in	 the	 animals.	
Conforming	pre-established	by	our	 lab	 (data	not	 showed)	 and	
in	classical	works	in	the	literature	(6,	10),	around	100 µg	of	MVs	
suspension	was	infused	intravenously	on	day	+1	and	day	+3	after	
cisplatin	 infusion	 (Figure	 S4B	 in	 Supplementary	Material).	 To	
evaluate	the	action	mechanism	of	MVs	during	in vivo	infusion,	
three	additional	groups	were	set	 in	parallel:	(i)	MVs	pretreated	
with	Proteinase	K	20 µg/mL	(Sigma,	USA)	and	DNase	I	(10 U/
µL;	 Stratagene,	 USA);	 (ii)	 MVs	 pretreated	 with	 a	 cocktail	 of	
proteases	 [Proteinase	K	 20  µg/mL	 (Sigma,	USA),	 trypsin	 (Life	
Technologies,	USA)	and	collagenase	1 A	(Sigma,	USA)];	and	(iii)	
MVs	pretreated	with	Proteinase	K	20 µg/mL	(Sigma,	USA)	and	
RNase	 A	 (100 mg/mL;	Thermo	 Scientific,	 USA),	 according	 to	
the	manufacturer’s	instructions.	At	day	4	after	cisplatin	admin-
istration,	with	or	without	MSC	or	MV	infusion,	all	groups	were	
euthanized	 using	 an	 overdose	 of	 anesthetic	 [xylazine	 (30 mg/
kg) + ketamine	(200 mg/kg)],	and	urine,	blood,	and	renal	tissues	
were	collected	and	maintained	at	−80°C	until	analyses.
renal physiological parameters
The	 creatinine,	 urea,	 and	 lactate	 analysis	 were	 performed	 to	
measure	 the	 status	 of	 renal	 function	 (n =  8).	 Creatinine	 was	
measured	using	the	Jaffe	modified	method	(Labtest	Diagnostic,	
Brazil).	Urea	concentration	was	analyzed	with	a	urea	kit	(Labtest	
Diagnostic,	 Brazil),	 according	 to	 the	 manufacturer’s	 specifica-
tions.	The	percentage	of	lactate	was	measured	using	Advia	1650	
equipment	 (Bayer,	 Germany),	 following	 the	 datasheet	 instruc-
tions.	All	 animals	were	periodically	 (each	 24 h	during	 4 days)	
monitored	for	gain	or	loss	of	body	mass	(n = 8).	Finally,	an	injury	
score	evaluation	was	determined	according	to	the	absolute	mean	
of	clinical	parameters	(Table	S3	in	Supplementary	Material).
histomorphometry of Kidney Tissue
Kidney	 fragments	 were	 fixed	 in	 buffered	 formaldehyde	 4%	
(pH =  7.0)	 and	 embedded	 in	 paraffin	 block.	 For	 each	 group,	
histological	 sections	of	4–5 µm	were	performed	and	 the	 slides	
were	stained	with	hematoxylin/eosin	(H&E).	For	a	quantitative	
evaluation	 of	 renal	 injury,	 clinical	 pathologic	 score	 of	 tissue	
damage	 was	 performed.	 Twenty-five	 fields	 from	 five	 slides	
were	 selected	 (in	magnification	 400×),	 and	 for	 all	 groups,	 the	
percentage	of	necrosis,	expansion	of	glomerular	cavity,	 tubular	
dilation,	detachment	of	epithelial	cells,	formation	of	renal	casts,	
and	inflammatory	infiltrates	were	evaluated.	All	these	parameters	
were	determined	here	as	tissue	injury	index.	A	pathological	score	
was	 assigned	 for	 each	 parameter,	 according	 to	 injury	 severity	
(0 = absent,	1 = mild,	2 = moderate,	and	3 =  severe).	Finally,	
an	 overall	 percentage	 score	 (e.g.,	 arithmetic	mean	 of	 all	 abso-
lute	 parameters)	 was	 generated	 following	 a	 direct	 comparison	
between	the	experimental	groups.
In Situ immunostaining
Tissue	 sections	 of	 3–4  µm	 were	 processed	 on	 silanized	 slides	
(n  =  5).	 The	 immunohistochemistry	 was	 performed	 using	
protein	 block	 reagent,	 an	 EnVision+/HRP-Dual	 Link	 kit,	
DAB	 (3-3)	 tetrahydrochloride	 and	 diaminobenxidine	 solu-
tion	 (Dako, Denmark),	 and	caspase	3	 antibodies	 (1:1,000,	Cell	
Signaling,	 USA),	 following	 the	 manufacturer’s	 specifications.	
Slides	 were	 hydrated	 and	 dehydrated	 through	 alcohol–xylene	
gradient	(30–100%),	washed	in	buffer,	and	stained	and	mounted	
in	Permount	solution	(Sigma,	USA).	To	check	the	percentage	of	
extracellular	matrix	deposition,	picrosirius	staining	(Sirius	red	in	
picric	acid	0.1%)	was	performed.	For	immunofluorescence	evalu-
ation,	kidney	tissue	fragments	were	frozen	in	Tissue	Tek	(Sakura,	
Japan)	and	4-µm	cryosections	were	processed.	Cells	were	fixed,	
permeabilized,	 and	 incubated	with	primary	antibodies	 (1:200),	
i.e.,	 anti-Ki-67	 (Abcam,	USA),	 followed	by	 secondary	antibod-
ies	 (1:400)	 conjugated	 to	FITC	 (Abcam,	USA).	Cells	were	 also	
counter-stained	with	DAPI	for	nuclei	visualization	(Vector	Labs,	
USA).	The	fluorescent	labeling	was	observed	using	fluorescence	
microscopy	(Nikon,	Japan).	For	the	detection	of	in situ	necrosis/
apoptosis,	the	TUNEL	assay	was	used	with	the	in situ	Cell	Death	
Detection	Kit	(Roche,	Germany),	following	the	general	informa-
tion	 contained	 in	 the	 manufacturer’s	 protocol.	 The	 following	
in situ	assays	such	as	(i)	renal	fibrosis	by	picrosirius	method,	(ii)	
cell	proliferation	(immunohistochemistry	to	Ki-67),	and	(iii)	cell	
death	 (immunohistochemistry	 to	 Caspase-3)	 were	 performed	
using	 the	 quantification	 of	 at	 least	 20–30	 fields	 (magnification	
200×)	with	software	developed	by	Nikon	(NIS	elements	micro-
scope	Nikon).
assessment of Oxidative stress and 
Determination of cytokines
The	 in  vivo	 tissue	 oxidative	 stress	 was	 evaluated	 indirectly	 by	
nitric	 oxide	 (NO)	 measurement	 using	 the	 Griess	 modified	
method	(n = 6).	In	addition,	the	renal	content	of	reduced	(GSH)	
and	 oxidized	 (GSSG)	 glutathione	 levels	 were	 assessed	 using	 a	
glutathione	fluorescent	detection	kit	 (BioVision,	USA),	 follow-
ing	 the	manufacturer’s	 instructions	 (n = 6).	The	animal	 serum	
cytokine	 profile	 was	 performed	 using	 a	 flow	 cytometry	 beads	
array	systems	with	Cytometric	Bead	Array	Kit	for	inflammation	
(BD	Bioscience,	USA),	according	to	the	manufacturer’s	recom-
mendations	(n = 6).
mirna expression profiling
Total	RNA,	including	small	RNAs	(miRNAs),	was	extracted	from	
all	kidney	tissues	with	a	miRNeasy	Mini	Kit	(50)	(Qiagen,	South	
Korea),	according	to	the	manufacturer’s	instructions	(n = 6	per	
group).	The	concentration,	quality,	and	integrity	of	RNA	samples	
were,	respectively,	checked	using	a	Nanodrop	spectrophotometer	
(Thermo	 Scientific,	USA)	 and	Bioanalyzer	 equipment	 (Agilent	
Technologies,	USA)	(n = 6	per	group).	Furthermore,	the	reverse	
transcription	of	total	RNAs	and	miRNAs	was	performed	using,	
respectively,	 the	 High	 Capacity	 kit	 (Life	 Technologies,	 USA)	
and	the	RT2	miRNA	First	Strand	Kit	(12)	(Qiagen,	South	Korea)	
(n = 6	per	group).	Gene	expression	levels	between	the	groups	of	
samples	were	measured	by	real-time	PCR	(RT-qPCR)	using	the	
TaqMan	system	(Life	Technologies,	USA)	(n = 6).	To	 translate	
miRNAs	into	cDNAs	was	used	the	miScript	II	RT	Kit,	following	
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all	 recommendations	 in	 datasheet	 (Qiagen,	 South	 Korea).	 For	
quantitative	 detection	 of	 pre-	 and	mature	miRNAs	 forms,	 the	
Syber	Green	PCR	kit	was	utilized	(Qiagen,	South	Korea).	At	gene	
expression	assays	normalization,	the	endogenous	HPRT	gene	was	
used	as	a	housekeeping	gene,	whereas	that	for	miRNA	reactions,	
the	endogenous	control	SNOR73A	was	used.	Finally,	the	reaction	
was	carried	out	using	the	ABI	Prism	7300	sequence	detection	sys-
tem	(Life	Technologies,	USA).	The	results	were	analyzed	through	
relative	quantification	method	according	to	formula:	10,000/2ΔCt,	
using	SDS	software	(Life	Technologies,	USA).	The	global	miRNA	
PCR	arrays	were	performed	in	96-well	plates	per	each	set	(3	set	
per	group),	following	the	recommendations	specified	in	the	prod-
ucts	catalogs:	RT2	SYBR	Green	ROX	qPCR	Master	Mix	(24)	and	
Mouse	miRNome	RT2miRNA	PCR	array	(528	miRNAs;	Qiagen,	
South	Korea).	Data	analysis	and	normalization	were	performed	
using	the	web-based	application	provided	on	the	manufacturer’s	
website	(Qiagen,	South	Korea).
network analysis of Differentially 
expressed mirnas and Their mrna 
Targets
Differentially	 expressed	 miRNAs	 were	 selected	 between	 the	
groups	using	the	QIAGEN	software	website	analysis.	Only	the	
miRNAs	that	had	at	least	fivefold	changes	in	expression	were	
included	 in	 further	 analysis.	 Furthermore,	 the	MIR@NT@N	
resource	 was	 used	 to	 identify	mRNAs	 that	 were	 targeted	 by	
the	 selected	 differentially	 expressed	miRNAs	 (18).	Then,	 we	
searched	 for	 overlaps	 in	 the	miRNA	 sets	 using	GeneVenn,	 a	
web	application	 for	comparing	 set	 lists	using	Venn	diagrams	
(19).	The	known	and	predicted	relationships	between	miRNAs	
and	 target	 genes	 were	 obtained	 from	 the	 DIANA	 Tools	 and	
MIR@NT@N	resource,	according	to	the	criteria	in	the	default	
parameters	 (18–21).	 We	 only	 selected	 those	 genes	 targeted	
by	 at	 least	 two	miRNAs	 to	 restrict	 our	 analysis	 to	 the	most	
relevant	 pairs	 of	 connected	miRNAs	 and	mRNAs.	 Pathways	
significantly	 enriched	with	 target	 genes	 were	 identified	with	
the	DIANA	Tools.	We	also	generated	miRNA–mRNA	networks	
to	visualize	the	relations	between	miRNA	and	their	predicted	
target	genes.	The	gene	ontology	(GO)	analysis	were	generated	
using	a	web-based	enrichment	software	analysis,	FunNet,	and	
the	networks	were	built	using	 the	Cytoscape	software,	which	
allows	 network	 editing	 and	 visualization	 of	 the	 molecular	
interactions	(22).
Overexpression and silencing of selected 
mirnas
To	validate	our	findings,	cultures	of	renal	tubular	cells	(2 × 105	
cells	per	well)	were	seeded	in	six-well	plates	to	further	addition	
of	 RNA	 oligos,	 in	 order	 to	 inhibit	 or	 to	 overexpress	 specific	
miRNAs	 (i.e.,	miR-21,	miR-377,	miR-880,	 and	miR-141).	The	
cells	were	submitted	to	a	transfection	process	using	the	N-TER	
kit	 (Sigma,	 USA),	 conforming	 to	 the	manufacturer’s	 instruc-
tions	(Qiagen,	South	Korea)	(n = 6).	According	at	its	respective	
oligos,	the	cells	were	transfected	with	miRNAs	mimics,	inhibi-
tors	or	scramble	oligos.	Additionally,	a	control	group	was	run	
in	 parallel	 with	 transfection	 reagent	 alone.	 Subsequently,	 all	
groups	were	submitted	to	cisplatin	for	48 h,	and	MV	treatment	
was	performed	 in	an	additional	group	conforming	previously	
described.
Western blotting
For	each	sample,	50 µg	of	renal	tissue	protein	extract	was	used	
for	 electrophoresis	 on	 10%	 polyacrylamide	 gels	 (SDS-PAGE).	
The	 immunostaining	was	 carried	 out	 with	 primary	 antibodies	
(β-actin/1:1,000,	 Sigma,	 USA;	 IKK-α/1:1,000,	 Cell	 Signaling,	
USA;	Argonaute	2/1:1,000,	Cell	Signaling,	USA;	Drosha/1:1,000,	
Cell	Signaling,	USA;	Dicer/1:1,000,	Imgenex,	India),	followed	by	
conjugated	secondary	antibodies	(anti-mouse	or	anti-rabbit	per-
oxidase/1:5,000,	Sigma,	USA).	Then,	the	membrane	was	revealed	
by	 chemiluminescence	methods	 using	 the	 ECL	 kit	 (Millipore,	
USA),	and	the	 images	were	acquired	on	GEN-BOX	equipment	
(Syngene,	UK)	(n = 5).	The	GeneSnap	software	and	GeneTools	
(Syngene,	UK)	were	used	to	 identify,	analyze,	and	quantify	 the	
gel	bands.
statistical analysis
Data	were	collected	and	presented	according	to	classical	descrip-
tive	statistics.	The	data	sets	were	tested	for	a	Gaussian	distribution	
by	a	Kolmogorov–Smirnov	test	with	Dallal–Wilkison–Lillie	for	a	
p	value,	and	further	statistical	inference	parametric	methods	were	
performed	for	all	analyses.	Student’s	t	and	one-way	ANOVA	tests	
(followed	by	Tukey	post-test)	were	used	to	determine	significant	
differences,	 respectively,	 between	 two	 or	 more	 independent	
sample	groups.	All	experimental	data	obtained	in	this	study	are	
represented	by	the	mean	and	SD	of	the	mean	(±SD),	and	statisti-
cal	 analyses	 were	 conducted	 considering	 a	 minimal	 statistical	
significance	(α)	at	5%	(p < 0.05).
resUlTs
Msc and Msc-MV Treatments promote 
Functional recovery
First,	we	performed	an	extensive	characterization	of	MSCs	and	
their	MVs.	MSCs	 in vitro	showed	the	classical	 features	of	mes-
enchymal	cells	such	as	fibroblast	colony-forming	unit	formation,	
fibroblast-like	 morphology,	 differentiation	 into	 mesodermal	
lineages	 (i.e.,	 adipocytes,	 chondrocytes,	 and	 osteoblasts),	 high	
proliferation	 index,	 and	 a	 distinctive	 immunophenotype	 with	
classical	MSCs	features	(Figure	S1	 in	Supplementary	Material).	
On	the	other	hand,	MVs	secreted	by	MSCs	displayed	spheroid	
morphology,	had	 small	 size	 (≈125 nm),	 exhibited	positivity	 to	
MSC	(i.e.,	CD105,	CD90,	and	CD44),	exosomes	(i.e.,	CD9	and	
CD63),	 and	 surface	 markers,	 and	 internally	 had	 the	 presence	
of	 miRNAs	 (<22  nt)	 and	 their	 biogenesis	 machinery	 (Dicer,	
Drosha,	and	Argonaut	2)	(Figure	S2	in	Supplementary	Material).	
Subsequently,	 we	 assessed	 the	 repair	 potential	 of	 MSCs	 and	
MSC-MV	treatment	 in	a	 toxic	model	of	AKI.	 Interestingly,	we	
demonstrated	 in  vivo	 after	 cisplatin	 administration	 that	 injec-
tions	 of	 both	 MSCs	 and	 MVs	 ameliorated	 physiologic	 injury	
parameters	such	as	weight	loss,	injury	scores,	and	renal	damage	
markers	(serum	creatinine	and	urea	levels;	Figures 1A–F;	Movies	
S1	and	S2	in	Supplementary	Material).	Moreover,	to	understand	
FigUre 1 | Msc and MV treatments promote tissue recovery. (a,b) Evaluation of weight loss; (c,D) determination of injury score; (e) serum creatinine levels; 
and (F) serum urea levels (*p < 0.05 compared with the saline/control group and &p < 0.05 compared with the cisplatin group). Cis, cisplatin; MSC, mesenchymal 
stromal cell; MVs, microvesicles.
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FigUre 2 | continued
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which	molecular	pattern	inside	MVs	was	promoting	tissue	repair,	
we	performed	a	pretreatment	of	MVs	with	RNAses	and	observed	
the	abrogation	of	the	therapeutic	effect.	By	contrast,	DNAses	and	
proteases	pretreatments	did	not	show	any	effect	(Figures 1E,F).	
Furthermore,	we	identified	 in situ	 in	histological	renal	sections	
treated	with	MSCs	and	MVs	an	improvement	in	tissue	regenera-
tion	status	as	observed	by	increase	in	the	proliferation	rate	(Ki-
67	staining)	and	reduction	of	the	 injury	score,	detected	mainly	
by	 reduction	of	 apoptosis	 index	 (active	 caspase	 3	 and	TUNEL	
assays)	and	interstitial	extracellular	matrix	deposition	(Sirius	red	
staining)	(Figure	S3	in	Supplementary	Material).
Msc and Msc-MV Therapies Modulate a 
set of prosurvival Molecules
In	 an	 attempt	 to	 investigate	 the	beneficial	 therapeutic	 effect	 of	
MSCs,	we	analyzed	in vivo	the	tissue	expression	of	molecules	that	
are	 involved	 in	 the	modulation	of	 renal	 toxic	 injury.	With	 this	
analysis,	we	detected	in	kidney	tissues	after	MSC	and	MV	therapy	
a	reduction	of	the	injury	markers	(e.g.,	lactate	index	and	Kim-1	
levels)	and	apoptosis	index	(i.e.,	Bcl-2/Bax	ratio)	when	compared	
to	 damage	 group	 alone	 (cisplatin)	 (Figures  2A–C).	Moreover,	
the	MSC	and	MV	infusion	decreased	the	renal	oxidative	stress	
by	 enhancing	 anti-oxidant	 enzymes	 levels	 (e.g.,	 GSH/GSSG	
FigUre 2 |  injury- and protective-related molecules are modulated after Msc or MV treatments. (a) Serum lactate levels; (b) Kim-1 expression, a 
renal damage marker; (c) BCL-2/Bax ratio; (D) glutathione reduced (GSH) and oxidized (GSSG) ratio (GSH/GSSG); (e) expression of heme oxygenase 1 
(HO-1); (F) tissue levels of nitric oxide (NO); (g) expression of hepatocyte growth factor; (h) expression of vascular endothelial growth factor; (i) expression of 
insulin-like growth factor type 1 (IGF); (J) serum levels of interferon gamma (IFN-γ); (K) serum levels of interleukin 2; (l) serum levels of tumor necrosis factor α 
(TNF-α); (M) serum levels of interleukin 10; (n) serum levels of interleukin 4; (O) serum levels of interleukin 17, and (p,Q) protein expression of IKK-α kinase 
(*p < 0.05 compared with the saline/control group and &p < 0.05 compared with the cisplatin group). Cis, cisplatin; MSC, mesenchymal stromal cell; MVs, 
microvesicles.
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ratio	and	HO-1)	and	 reducing	 free	 radicals	presence	 (i.e.,	NO;	
Figures  2D–F).	 Concomitantly,	 we	 observed	 in	 kidney	 tissues	
treated	with	both	MSCs	and	MVs	an	increase	in	the	expression	
of	classical	cytoprotective	genes	such	as	hepatocyte	growth	fac-
tor,	vascular	endothelial	growth	factor,	and	IGF	(Figures 2G–I).	
In	 addition,	 mice	 transplanted	 with	 MSCs	 or	 MVs	 showed	 a	
decrease	in	the	serum	inflammatory	cytokine	levels	(i.e.,	interleu-
kin	2,	interleukin	17,	TNF-α,	and	INF-γ)	and	an	increase	in	anti-
inflammatory	molecules	such	as	interleukin	10	and	interleukin	4	
(Figures 2J–O).	Finally,	the	NF-κB	signaling	pathway,	which	is	
associated	with	acute	inflammation,	was	also	downregulated	in	
renal	tissues	after	MSCs	and	MVs	intervention,	as	demonstrated	
by	the	reduction	of	IKK-α	protein	expression	(Figures 2P,Q).
Msc and Msc-MV Treatments promote In 
Vitro cytoprotection and cellular 
recovery
To	support	our	 in vivo	findings,	we	evaluated	the	cross-talking	
between	MSCs	and/or	MVs	with	 tubular	epithelial	cells.	Using	
in  vitro	 co-culture	 assays,	 we	 observed	 after	 cisplatin	 stimulus	
that	 both	 treatments	 (MSC	 and	MVs)	 reduced	 cell	 death	 fre-
quency	(i.e.,	apoptosis/necrosis	ratio)	and	oxidative	stress	index	
(i.e.,	anion	superoxide	level)	while	promoting	an	increase	in	the	
cellular	proliferative	rates,	thereby	indicating	that	MSCs	and	MVs	
can	restore	the	tubular	epithelial	cell	physiology	after	toxic	injury	
(Figure 3).
Msc Treatment Modulates the global 
mirna profile in renal Tissue
In	 search	 for	 precise	 molecular	 mechanisms	 involved	 in	 the	
MSC-mediated	 cytoprotection,	we	analyzed	 the	global	miRNA	
profile	 changes	 in	 the	 renal	 tissue	 submitted	 to	 toxic	 injury	
alone	 or	 treated	 with	MSCs	 (Figure  4A).	We	 detected	 a	 total	
of	 528	 miRNAs	 expressed	 in	 common	 between	 all	 the	 tested	
conditions	 (Figure  4A;	 Figure	 S1	 in	 Supplementary	Material),	
in	 which	 39	 were	 upregulated	 and	 37	 were	 downregulated	 in	
the	 cisplatin	 condition	 when	 compared	 with	 saline	 at	 a	 fold	
change	 ≥3	 (Figures  4B,D).	 After	 MSC	 therapy,	 50	 miRNAs	
were	 upregulated	 and	 11	miRNAs	 were	 downregulated	 in	 the	
cisplatin + MSCs	condition	when	compared	with	cisplatin	alone,	
considering	a	fold	change	≥3	(Figure 4B).	Further,	we	observed	
that	 the	 proteins	 related	 to	 miRNA	 biogenesis	 (e.g.,	 Dicer,	
Drosha,	and	Argonaut	2)	were	all	modulated	during	toxic	injury,	
and	after	MSC	administration,	they	had	their	physiologic	levels	
re-established	 (Figure  4C).	 These	 results	 were	 complemented	
by	 miRNA	 amount	 analysis,	 which	 showed	 higher	 miRNA	
levels	 during	 injury	 process	 and	 lower	 levels	 after	MSC	 treat-
ment	(Figure	S4A	in	Supplementary	Material).	Additionally,	we	
FigUre 3 | continued
(Continued )
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FigUre 3 | Msc and MV treatment promoted cell recovery (a) Evaluation of cell death, apoptosis (Annexin V), and the necrosis (7-AAD) index;  
(b) determination of cell proliferation score (Cell Trace Ratio); and (c) analysis of oxidative stress and superoxide anion radical activity (O2
⋅−) (*p < 0.05 compared 
with the saline/control group and &p < 0.05 compared with the cisplatin group). Cis, cisplatin; MSC, mesenchymal stromal cell; MVs, microvesicles; Tub, murine 
renal tubular epithelial cell line MM55.K.
10
de Almeida et al. Mesenchymal-Cells Fit a Regulatory Network
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 7 | Article 645
observed	that	the	differential	changes	in	the	miRNA	signatures	
were	 associated	 with	 a	 broad	 modulation	 of	 specific	 miRNAs	
associated	with	 cisplatin	or	MSC	 intervention	 (Figures  4C,D).	
Therefore,	we	decided	to	narrow	our	downstream	analysis	to	the	
highly	modulated	miRNAs	(fold	change	≥5)	at	each	comparison.	
In	the	cisplatin	condition	compared	to	saline,	we	found	that	miR-
377,	miR-741,	miR-675-3p,	miR-21,	miR-463,	and	miR-293*	were	
the	most	upregulated	miRNAs,	whereas	miR-141,	miR208a,	miR-
92a*,	 miR-292-3p,	 miR-673-5p,	 and	 miR-1190	 were	 the	 most	
downregulated	miRNAs	 (Figure  4D).	When	 we	 evaluated	 the	
cisplatin + MSCs	condition	in	comparison	with	cisplatin	alone,	
we	detected	the	miR-141,	miR-880,	miR-433,	miR-92a,	miR-463,	
and	miR-295	as	most	upregulated	miRNAs,	while	the	miR-30e,	
miR-377,	miR543,	miR-693-5p,	miR-201,	and	miR148a*	were	the	
most	downregulated	ones	(Figure 4D).	Subsequently,	we	identi-
fied	the	protein-coding	genes	that	were	predicted	to	be	targets	of	
the	top	differentially	expressed	miRNAs	at	each	comparison	and	
looked	 for	biological	pathways	 that	were	 significantly	enriched	
with	those	genes.	Thus,	with	this	approach,	we	found	signaling	
pathways	related	to	tissue	repair	and	homeostasis	recovery,	such	
as	 regulation	 of	 actin,	 axon	 guidance,	 ErbB,	 P13K-Akt,	 Wnt,	
MAPK,	 insulin,	 protein	 processing,	 and	 ubiquitin/proteolysis	
(Figure 4E).	A	brief	description	of	all	pathways	associated	with	
the	differentially	expressed	miRNAs	at	each	comparison	and	their	
predicted	target	genes	is	illustrated	in	Table	S2	in	Supplementary	
Material.	In	addition,	the	GO	analysis	using	the	mRNAs	targeted	
by	miRNAs	showed	that	the	majority	of	the	highly	regulated	miR-
NAs	in	renal	tissues	are	linked	to	positive	regulation	of	transcrip-
tion	DNA-dependent	biological	processes,	 thereby	highlighting	
a	 presence	 of	 intrinsic	 regulatory	 mechanism	 (Figure  4F).	
In	 attempt	 to	 verify	 if	 the	miRNAs	 differentially	 expressed	 in	
renal	 tissues	were	 directly	 transferred	 by	MVs,	we	 carried	 out	
a	 miRNAs	 profile	 of	 MVs	 and	 MSCs	 and	 detected	 a	 higher	
number	of	miRNAs	upregulated	in	MVs	than	MSCs	(Figure	S5A	
in	 Supplementary	 Material).	 Moreover,	 we	 identified	 that	 the	
top	modulated	miRNAs	were	not	directly	associated	 to	kidney	
miRNA	profile	and	the	miR-377	and	miR-141	(mostly	regulated	
in	renal	tissues),	although	present	inside	of	MVs,	they	were	not	
found	to	be	enriched	into	MVs	(Figures	S5B,C	in	Supplementary	
Material).	These	findings	 suggest	 that	MVs	 and	MSCs	did	not	
share	the	same	miRNA	profile	and	its	effect	in	the	renal	tissue	can	
be	conducted	by	an	indirect	regulatory	process.
an integrative network analysis revealed 
the role of specific mirnas in aKi and in 
cytoprotection promoted by Mscs
In	order	to	identify	some	biological	functions	attributed	to	MSC	
renoprotection,	 we	 carried	 out	 an	 in  silico	 analysis	 with	 the	
most	 upregulated	 and	 downregulated	miRNAs	 in	 the	 cisplatin	
condition	compared	to	saline	and	connected	these	miRNAs	with	
previously	 described	 differentially	 expressed	 genes	which	were	
associated	 to	 cisplatin	 damage	 in	 renal	 tissues	 (Figure	 S6A	 in	
Supplementary	Material)	 (23,	24).	 After	 cisplatin	 intervention,	
we	observed	 that	 the	upregulated	 and	downregulated	miRNAs	
(red/green	triangles)	in	renal	tissues	were	strongly	integrated	in	
the	network,	considering	that	the	top	miRNAs	in	terms	of	fold	
change	 (yellow	 border	 triangles)	 showed	 interactions	with	 key	
molecules	altered	in	kidney	injury	(blue	and	orange	rectangles)	
(Figure	 S6A	 in	 Supplementary	 Material).	 Moreover,	 using	 a	
functional	and	enrichment	approach,	we	verified	in	this	miRNA–
mRNA	 network	 that	 the	 top	 miRNAs	 in	 fold	 change	 (yellow	
border	triangles)	also	interacted	with	specific	genes	involved	in	
TGF-β/Wnt	 (purple	 border	 rectangles)	 and	 fibrosis/epithelial–
mesenchymal	 transition	 (EMT)	 (orange	 rectangles)	 signaling	
pathways	(Figure	S6A	in	Supplementary	Material).	Furthermore,	
to	 heighten	 our	 inference	 analysis,	 we	 compared	 in	 a	 Venn	
diagram	 all	 the	 miRNA	 profiles	 and	 selected	 the	 10	 miRNAs	
FigUre 4 | The global mirna signature of renal tissues after Msc treatment.  
(Continued )
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FigUre 5 | mirna–mrna network in cytoprotection induced by Mscs. (a) MSCs-modulated network showing the interactions between miRNAs modulated 
by MSCs and putative targets genes interacting with at least two of these altered miRNAs, and (b) Venn diagrams depicting overlapping miRNA target genes 
obtained from three microRNA target prediction tools (TargetScan, miRanda, and miRDB) and a list of overlapping potential target genes for the top two differentially 
expressed miRNAs in the MSCs-modulated network (i.e., miR-141 and miR-377). Upregulated and downregulated miRNAs are represented, respectively, as red 
and green triangles. The top miRNAs in terms of fold changes had their border colors altered to yellow. Genes previously linked to fibrosis or epithelial–mesenchymal 
transition are represented as orange rectangles. Genes that were previously related to the TGF-β or Wnt pathways additionally had their border colors altered to 
purple and unrelated genes are represented in blue rectangles. Cis, cisplatin; MSCs, mesenchymal stromal cells; MVs, microvesicles.
(a) Heat map analysis of miRNA profile for all comparisons; (b) scatter plots representing the differentially expressed miRNAs with a fold change ≥3: (i) cisplatin in 
comparison to saline and (ii) cisplatin + MSC in comparison with cisplatin alone; (c) expression levels of proteins involved in miRNA biogenesis (Dicer 1, Drosha, and 
Argonaut 2); (D) bar plot of differentially expressed miRNAs with a fold change ≥3 at each comparison; (e) signaling pathways associated to genes predicted to be 
target of the top differentially expressed miRNAs; and (F) gene ontology analysis of biological processes linked to the top regulated miRNAs for all comparisons 
(*p < 0.05 compared with the saline/control group and &p < 0.05 compared with the cisplatin group). Cis, cisplatin; MSC, mesenchymal stromal cell; MVs, 
microvesicles.
FigUre 4 | continued
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(overlapping*)	that	were	exclusively	related	to	MSC	cytoprotec-
tion	 (Figure	 S6B	 in	 Supplementary	Material).	 Interestingly,	we	
also	 identified	 in	 this	 overlap	 two	miRNAs	 (i.e.,	miR-141	 and	
miR-377)	 that	 were	 inversely	 regulated	 between	 the	 “injury 
profile”	(Cis	vs.	Saline)	vs.	the	“treatment profile”	(Cis + MSC	vs.	
Cis)	(Figure 4D;	Figure	S6B	in	Supplementary	Material).	After,	
using	 these	 10	 pre-selected	miRNAs,	we	 constructed	 a	 second	
miRNA–mRNA	 network	 (“regulatory network”)	 and	 identified	
their	 corresponding	 predicted	 target	 genes	 (Figure  5A).	Then,	
we	 selected	 only	 the	 genes	 that	 were	 targeted	 by	 at	 least	 two	
miRNAs	in	order	to	visualize	the	most	relevant	miRNA–mRNA	
interactions	 (Figure  5A).	 In	 this	 second	 regulatory	 network,	
the	most	connected	miRNAs	were	over	again	the	miR-141	and	
miR-377	 (yellow	 border	 triangles)	 (Figure  5A).	 Subsequently,	
after	 enrichment	 analysis,	 we	 extracted	 semantic	 relationships	
between	these	miRNAs	and	again	verified	connection	with	genes	
related	to	the	TGF-β/Wnt	(purple	border	rectangles)	and	fibro-
sis/EMT	 (orange	 rectangles)	 signaling	 pathways	 (Figure  5A).	
Furthermore,	in	search	of	specific	functions	associated	to	these	
most	connected	miRNAs	(e.g.,	miR-141	and	miR-377),	we	built	a	
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second	Venn	diagram	with	additional	putative	target	genes	pre-
dicted	by	three	distinct	databases,	i.e.,	Targetscan,	miRanda,	and	
miRDB	(Figure 5B).	Finally,	the	results	from	this	second	Venn	
diagram	revealed	three	potential	 target	genes	for	miR-141	(i.e.,	
Yaf2,	Ulk2,	and	Ccne2)	and	eight	potential	target	molecules	for	
miR-377	(i.e.,	Ncoa6,	Bend6,	Nts,	Cul1,	Pitx2,	Zfp36l1,	Ssfa2,	and	
Rsbn1)	(Figure 5B).	Thus,	based	on	its	biologic	importance	and	
considering	the	renal	context	of	injury	and	repair,	only	the	most	
representative	target	genes	(i.e.,	Ulk2	and	Cul1)	were	selected	to	
validation	step	analysis.
mirnas actively participate in Tissue 
injury and repair during aKi
To	validate	the	participation	of	miR-377	and	miR-141	in	tissue	
injury	 and	 repair,	we	 evaluated	 the	dynamic	 expression	of	 the	
precursor	and	mature	 forms	of	 these	miRNAs.	Cisplatin	 treat-
ment	 in  vivo	 increased	 both	 mature	 and	 pre-miR-377	 levels,	
proportionally	to	the	damage	severity	(Figure 6A).	Conversely,	
the	 renal	 tissue	 expression	 of	 both	 mature	 and	 pre-miR-141	
species	 was	 higher	 when	 the	 injury	 was	 absent	 and	 lower	
when	the	damage	process	was	already	established	(Figure 6B).	
Conforming	observed	at	MSCs	treatment	in	our	global	miRNA	
profile	(Cis + MSCs	vs.	Cis),	the	treatment	with	MVs	also	reduced	
abruptly	the	miR-377	expression	and	increased	the	levels	of	miR-
141	 in	 renal	 tissues	 submitted	 to	 toxic	 injury	 (Figures  6A,B).	
Interestingly,	 the	 detection	 of	 the	 pre-miR-377	 in	 early	 stages	
of	 the	 renal	 tissue	 injury	 suggests	 that	 its	 expression	 could	 be	
used	as	a	potential	marker	of	AKI	(Figure 6A).	Concordantly,	
we	 observed	 similar	 results	 using	 tubular	 cells	 in  vitro,	 which	
showed	 elevated	 expression	 of	 mature	 miR-377	 during	 toxic	
injury	progression,	considering	that	the	levels	of	mature	miR-141	
decreased	at	the	same	time	points	(Figures 6C,D).	Surprisingly,	
we	also	observed	 in vitro	 that	treatment	with	MVs	was	able	to	
decrease	miR-377	 expression	 and	 increase	 the	miR-141	 levels	
when	compared	to	cisplatin-treated	cells	alone	(Figures 6C,D).	
According	 to	 the	damage	 severity,	we	 also	 observed	 in  vitro	 a	
premature	 expression	 of	 pre-miR-377	 than	 its	 mature	 form	
(miR-377),	whereas	the	pre-miR-141	expression	remained	unal-
tered	(Figures 6C,D).	For	elucidating	the	incorporation	process	
of	MVs	 by	 tubular	 epithelial	 cells,	we	 added	pre-stained	MVs	
suspensions	 (MVs	 labeled	with	fluorescent	 red	dye)	 to	 injured	
tubular	cells	cultures	(cultured	with	cisplatin)	and	analyzed	its	
progressive	 incorporation	 per	 24  h	 in	 a	 time-lapse	 assay.	We	
observed	that	MVs,	although	in	aggregated	status,	are	internal-
ized	by	epithelial	tubular	cells	(dim	red	dots	and	black	arrows)	
with	 predominant	 localization	 in	 the	 cytoplasm	 (Figure  6E;	
Movie	S3	in	Supplementary	Material).
The mirna–mrna interaction plays a 
Fundamental role in Msc-Mediated 
protection
To	investigate	the	role	of	miRNA–mRNA	interactions	on	kidney	
injury	progression	 and	 tissue	 recover	 after	MSC	 treatment,	we	
conducted	 an	 in  vitro	 transfection	 assay	 in	 tubular	 epithelial	
cells	using	specific	oligos	that	work	as	mimics	and	inhibitors	of	
some	of	the	most	relevant	miRNAs	found	in	our	miRNA	profile	
analysis	(i.e.,	miR-880,	miR-141	miR-377,	and	miR-21).	First,	we	
validated	our	transfection	assays	by	demonstrating	that	all	inhibi-
tors	and	mimic	oligos	efficiently	overexpressed	or	silenced	their	
correspondent	 target	 molecules	 (Figure	 S7	 in	 Supplementary	
Material).	 Then,	 we	 observed	 in	 tubular	 cells	 submitted	 to	
cisplatin	 treatment	 a	 protection	 against	 cell	 death	 (reduction	
in	 apoptosis/active	 caspase-3	 and	 necrosis/7-AAD	 expression	
levels)	 only	 in	 cells	 incubated	 with	 inhibitors	 of	 miR-21	 and	
miR-377	 (Figure  7A).	 Complementary,	 the	 intracellular	 level	
of	 anion	 superoxide	 (O2
− ,	 a	 stress	 oxidative	 radical)	 decreased	
only	 in	 cells	 treated	 with	 inhibitors	 of	 miR-21	 and	 miR-377	
(Figure 7B).	By	contrast,	the	use	of	miR-880	and	miR-141	mim-
ics,	which	were	 elevated	 in	 tissues	 treated	with	MSCs,	 did	not	
show	 any	 direct	 protective	 effect	 on	 tubular	 cells	 submitted	 to	
toxic	injury	(Figures 7A,B).	In	addition,	the	 in vitro	 inhibition	
of	miR-377	 in	 tubular	 epithelial	 cells	 promoted	 an	 increase	 in	
the	 expression	 of	 cytoprotective	 genes	 (i.e.,	 BCL-2	 and	HO-1;	
Figures	 S8A,B	 in	 Supplementary	Material)	 and	 a	 reduction	 in	
damage-related	molecules	(i.e.,	Kim-1	and	iNOS;	Figures	S8C,D	
in	Supplementary	Material).	The	absence	of	any	significant	effects	
in	 the	 control	 (cells	 without	 cisplatin	 stimulus),	 the	 negative	
control	 (cells	 only	 exposed	 to	 transfection	 reagents),	 and	 the	
scrambled	oligos	groups	(miRNA	control,	cells	treated	with	not	
associated	miRNAs)	 corroborated	 the	 relevance	 of	 our	 results	
(Figures  7A,B;	 Figures	 S7A–D	 and	 S8A–D	 in	 Supplementary	
Material).	 In	 sequence,	 we	 selected	 potential	 target	 genes	 for	
miR-141	 (i.e.,	 Ulk2)	 and	 miR-377	 (i.e.,	 Cul1)	 and	 confirmed	
in  vitro	 and	 in  vivo	 their	 inverse	 relationships.	 Specifically,	we	
identified	 in  vitro	 that	Ulk2	 expression	 increased	under	 injury	
conditions	but	after	MVs	treatment	or	miR-141	overexpression	
had	 its	 levels	 decreased	 when	 compared	 to	 cisplatin-treated	
cells	 alone	 (Figure  7C).	These	 results	 were	 further	 confirmed	
in  vivo	 by	demonstrating	 that	 the	Ulk2	 levels	were	 elevated	 in	
tissues	 damaged	 by	 cisplatin	 and	 decreased	 after	MSC	 or	MV	
treatment	(Figure 7C).	In	parallel,	we	also	showed	in vitro	that	
Cul1	expression	was	higher	in	normal	conditions	and	decreased	
after	cell	injury	(Figure 7D).	Conversely,	the	in vitro	Cul1	levels	
were	enhanced	after	MV	therapy	or	when	miR-377	was	silenced	
in	comparison	with	cisplatin	group	alone	(Figure 7D).	Finally,	
in vivo	measurements	showed	that	Cul1	levels	were	lower	during	
AKI	but	increased	in	renal	tissues	after	MSC	or	MV	administra-
tion	(Figure 7D).
DiscUssiOn
In	order	to	maintain	tissue	turnover,	the	cross-talk	between	cells	
is	a	required	and	organized	process	that	contributes	significantly	
to	horizontal	molecular	exchange	(25).	MVs	are	emerging	as	key	
mediators	of	cell-to-cell	communication	that	underpin	the	main-
tenance	of	physiological	processes	and	tissue	development	(26).	
Thus,	the	concept	that	MVs	can	modulate	the	fate	of	target	cells	
via	the	genetic	transfer	of	information	is	an	emerging	paradigm	
in	regenerative	medicine	(27).
In	an	attempt	to	investigate	this	mechanism,	we	hypothesized	
that	MSCs	mediate	tissue	repair	by	secreting	MVs	that	transcrip-
tionally	modulate	 the	molecular	 pattern	 in	 injured	 renal	 cells.	
Initially,	using	an	experimental	model	of	cisplatin-induced	AKI,	
FigUre 6 | Kinetics of expression of the top differentially expressed pre- and mature mirnas after Msc or MV treatments and MVs incorporation. 
(a) Expression of mature and pre-miR-377 in renal tissues with progressive damage by cisplatin; (b) expression of mature and pre-miRNA-141 in renal tissues with 
progressive damage by cisplatin; (c) expression of mature and pre-miR-377 in MM55.K tubular cells with progressive damage by cisplatin and MVs treatment; (D) 
expression of mature and pre-miR-141 in MM55.K tubular cells with progressive damage by cisplatin and MVs treatment; and (e) progressive time-course assay of 
in vitro MVs incorporation (dim red dots and black arrows) into tubular epithelial cells per 24 h, also demonstrated in Movie S3 in Supplementary Material (*p < 0.05 
compared with the saline/control group and &p < 0.05 compared with the cisplatin treatment, 15 and 20 mg/kg, 24 and 48 h). Cis, cisplatin; MSC, mesenchymal 
stromal cell; MVs, microvesicles.
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FigUre 7 | Functional validation of differentially expressed mirnas and their predicted targets.  
(Continued )
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(a) Evaluation of cell death frequency in MM55.K cells submitted to toxic injury with overexpression of miR-141 and miR-880 or silencing of miR-377 and miR-21 
expressions; (b) evaluation of oxidative stress in MM55.K cells submitted to toxic injury with overexpression of miR-141 and miR-880 or silencing of miR-377 and 
miR-21 expressions; (c) validation in vitro and in vivo of the potential target of miR-141 (Ulk2), and (D) validation in vitro and in vivo of the potential target of miR-377 
(Cul 1) (*p < 0.05 compared with the saline/control group and &p < 0.05 compared with the cisplatin group). Cis, cisplatin; MSC, mesenchymal stromal cell; MVs, 
microvesicles; Tub, renal tubular cells.
FigUre 7 | continued
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we	demonstrated	in vivo	and	in vitro	that	MVs,	although	by	dis-
tinct	mechanisms,	mimic	the	beneficial	effects	of	MSC	treatment	
modulating	 a	 prosurvival	 program	 and	 inhibiting	 cell	 death.	
Furthermore,	we	identified	a	prominent	participation	of	miRNAs	
as	main	protagonists	in	the	regulation	of	this	protective	effect.
In	 this	 sense,	 the	 miRNA	 profile	 has	 been	 characterized	
in	 our	 study	 and	we	 verified	 a	 distinct	 pattern	 between	MSCs	
and	MSC-MV	profiles.	Moreover,	 the	enriched	miRNAs	 inside	
MVs	were	not	directly	associated	with	most	regulated	miRNAs	
in	renal	tissues	suggesting	an	indirect	regulatory	role	of	MSCs/
MVs-derived	 miRNAs.	 A	 recent	 work	 have	 conducted	 a	 GO	
analysis	 of	 predicted	 and	 validated	 targets	 of	 highly	 expressed	
miRNAs	in	MSCs	and	MVs,	and	the	authors	demonstrated	that	
these	modulated	miRNAs	could	be	associated	with	 the	control	
of	multi-system	and	-organ	development,	 immune	system,	cel-
lular	 differentiation,	 and	 cell	 survival	 (6).	 In	 fact,	 we	 showed	
here,	in vitro	and	in vivo,	that	markers	related	to	cytoprotection,	
oxidative	 stress,	 apoptosis,	 and	 inflammation	 were	 modulated	
after	MSCs	and	MVs	therapies.	In	this	landscape,	we	analyzed	the	
global	miRNA	signature	in	renal	tissues	after	MSC	treatment	and	
observed	at	the	predicted	target	genes	of	the	most	differentially	
expressed	miRNAs	a	preferential	association	with	ErbB,	P13K-
Akt,	Wnt,	and	MAPK	signaling	pathways	(Figure 4E).
These	 pathways	 play	 an	 essential	 role	 in	 tissue	 recover	 and	
development,	 as	 well	 as	 coordinate	 cellular	 health	 physiology.	
Indeed,	a	previous	study	from	our	group	already	demonstrated	
the	participation	of	MAPK,	ErbB,	and	Wnt	signaling	pathways	
during	 renal	 damage	 progression	 and	 their	 modulation	 after	
treatment	with	cytoprotective	and	anti-oxidant	molecules	 (28).	
Moreover,	 different	 studies	 have	 established	 an	 interesting	
interplay	 between	 the	 Notch–PI3K/Akt	 and	 mTOR–PI3K/Akt	
pathways	in	the	regulation	of	renal	cells	physiology	(29–31).	In	
line	 with	 this	 evidence,	 our	 results	 here	 demonstrated	 a	 strict	
association	between	differentially	modulated	miRNAs	with	regu-
latory	pathways	linked	to	positive	modulation	of	transcription-
dependent	 biological	 process,	 thereby	 highlighting	 the	 role	 of	
MSCs	and	MVs	to	restore	normal	renal	function	after	AKI.
Furthermore,	we	were	able	 to	correlate	 the	miRNA	changes	
in	cisplatin-induced	AKI	with	published	mRNA	alterations	that	
had	 been	 previously	 linked	 to	 cisplatin	 damage.	 Interestingly,	
this	first	miRNA–mRNA	network,	“injured network,”	 related	 to	
toxic	injury	was	mainly	associated	with	alterations	in	TGF-β/Wnt	
and	fibrosis/EMT	signaling	pathways.	Subsequently,	our	second	
mRNA–miRNA	 network,	 “regulatory network,”	 which	 was	
comprised	by	10	pre-selected	miRNAs	found	in	the	overlapping	
(Figure	 S6B	 in	 Supplementary	Material),	 showed	 again	 a	 close	
link	between	these	miRNAs	with	genes	enriched	in	the	TGF-β/
Wnt	 and	 fibrosis/EMT	 signaling	 pathways.	This	 evidence	 is	 in	
accordance	with	previous	results	describing	the	reciprocal	inter-
actions	between	miRNAs	and	Wnt	genes	during	kidney	disease	
progression	(32).	The	Wnt	pathway	is	involved	in	development,	
injury	 repair,	 tissue	 homeostasis,	 and	 progressive	 fibrosis	 (33,	
34).	Indeed,	the	activation	of	canonical	Wnt	signaling	is	required	
for	TGF-β-mediated	fibrosis	(35).	Fibrosis	is	related	to	a	chronic	
pathologic	status,	and	it	is	postulated	that	EMT	is	a	potent	pro-
fibrotic	process,	which	primarily	is	activated	by	TGF-β	(36).	Thus,	
considering	 a	 context	 of	 toxic	AKI,	 the	 search	 for	Wnt/TGF-β	
related	targets	may	be	an	interesting	strategy	to	understand	how	
MSCs	elicit	their	therapeutic	properties.
Complementarily,	 the	 use	 of	 miRNA–mRNA	 network	
analysis	allowed	us	to	understand,	in	a	systematic	and	integrative	
perspective,	how	miRNAs	are	linked	to	their	specific	target	genes.	
Additionally,	 we	 identified	miR-377	 and	miR-141	 as	 the	most	
connected	miRNAs	in	the	MSC-modulated	network	(regulatory 
network),	 thereby	 indicating	 their	eminent	participation	 in	 the	
MSC-protective	 effect	 against	 renal	 toxic	 damage.	 In	 agree-
ment	with	this,	we	found	in vitro	and	in vivo	that	both	pre-	and	
mature	miRNAs	corresponding	species	were	inversely	regulated	
during	AKI	and	had	their	 levels	normalized	after	MSC	or	MV	
administration.	Then,	using	specific	silence	oligos,	we	revealed	
in vitro	the	direct	participation	of	miR-337	in	the	mediation	of	
cell	death	and	oxidative	stress	process	in	injured	tubular	cell.	In	
particular,	 miR-377	 is	 overexpressed	 in	 renal	 chronic	 disease	
and	 its	 expression	 is	 associated	with	 fibronectin	 accumulation	
(37).	 In	fact,	TGF-β	expression	positively	regulates	miR-377	in	
diabetic	nephropathy	(38).	Moreover,	miR-377	promotes	matrix	
deposition	 and	 thereby	 directly	 contributes	 to	 pro-fibrotic	
response	elicited	by	TGF-β	(39).	Conversely,	the	miR-141	levels	
are	 reduced	 in	 renal	disease	 and	 cancer	 (40,	41).	Additionally,	
miR-141	 expression	 is	 negatively	 regulated	 by	 TGF-β,	 which	
promotes	EMT	and	fibrosis	via	a	Smad-dependent	signal	 (42).	
Taken	together,	these	results	suggest	that	the	inverse	regulation	of	
miR-377	and	miR-141	may	represent	the	molecular	mechanisms	
underlying	 to	 MSC	 protection,	 considering	 here	 a	 context	 of	
cisplatin-induced	kidney	injury.
To	document	this	interesting	connection,	we	identified	puta-
tive	 targets	genes	 for	 these	 specific	miRNAs	(i.e.,	miR-377	and	
miR-141)	and	evaluated	their	expression	in vitro	and	in vivo.	We	
showed	that	Ulk2	(predicted	target	of	miR-141)	is	widely	regu-
lated	by	miR-141	and	Cul1	(predicted	target	of	miR-377)	level	is	
directly	affected	by	miR-377	expression.	Cul1	is	fundamental	to	
normal	embryogenesis	and	participates	in	ubiquitin	proteolytic	
system	regulation,	whereas	its	deletion	in	mice	causes	the	accu-
mulation	of	cyclin	E,	which	leads	to	cell-cycle	arrest	and	chromo-
some	 instability	 (43,	44).	The	essential	 function	of	Ulk2	 is	not	
entirely	elucidated,	but	studies	have	suggested	its	evolutionarily	
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participation	in	the	regulation	of	autophagy,	cytoskeleton	reor-
ganization,	 vesicle	 traffics,	 and	 adaptation	 to	 stress	 stimulus,	
including	starvation	(45–47).
The	precise	mechanism	whereby	MSC	protects	 tissue	 injury	
can	be	designed	as	 “many-worlds interpretation”	process;	how-
ever,	here	we	demonstrated	that	the	interplay	between	miRNAs	
and	 their	 mRNA	 targets	 represents	 a	 new	 and	 unexplored	
mechanism	by	which	MSCs	can	restore	kidney	tissue	function.	
In	summary,	our	experimental	validation	and	in silico	prediction	
suggest	that	miRNAs	conveyed	by	MSC-MVs	could	participate	in	
the	modulation	of	an	inner	cell	program	in	target	damage	renal	
cells	re-establishing	tissue	global	homeostasis	and	system	recov-
ery.	Thus,	the	fine	tuning	of	miRNA–mRNA	regulatory	networks	
may	 underlie	 some	 of	 the	 protective	 effects	 induced	 by	MSCs	
or	MVs	in	the	renal	tissues	providing	a	better	understanding	of	
kidney	injury/recover	process.	Furthermore,	we	believe	that	our	
main	 findings	 illustrated	 here	may	 contribute	 substantially	 for	
development	 of	 new	 and	 prospective	 therapeutic	 strategies	 for	
acute	and	chronic	kidney	diseases.
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